PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Protalix BioTherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.56−0.06 (-2.29%)
Close on Oct 19, 2026
- Market cap
- $211.35M
- P/E (TTM)
- 11.1
- Dividend yield
- –
Protalix BioTherapeutics, Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Single operating segment | $19.90M | – | – | – | $15.66M | – | – | – | – | – | – | – | 100.0% | +27.1% |
| Single reporting segment | – | $33.75M | – | $17.85M | $15.66M | $10.11M | – | $17.96M | $13.47M | – | – | – | – | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOODS | $19.83M | $7.42M | $8.69M | $17.67M | $15.44M | $10.00M | $18.16M | $17.84M | $13.30M | $3.68M | $10.11M | $10.17M | 99.7% | +28.4% |
| LICENSE AND R&D SERVICES | $68.00K | $26.33M | $428.00K | $178.00K | $218.00K | $118.00K | $57.00K | $120.00K | $170.00K | $71.00K | $377.00K | $177.00K | 0.3% | -68.8% |
By region
From the segment and revenue-disaggregation notes of Protalix BioTherapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.